A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Trial details
- Registry ID
- NCT07200908
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Hepcludex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908 | MIRM | Phase 3 | Recruiting | 2027-06-30Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |